

Joseph A Pinto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6101411/publications.pdf>

Version: 2024-02-01

68
papers

1,862
citations

516710

16
h-index

276875

41
g-index

70
all docs

70
docs citations

70
times ranked

3680
citing authors

#	ARTICLE	IF	CITATIONS
1	Sex, immunity, and cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2022, 1877, 188647.	7.4	7
2	Neoadjuvant pertuzumab in nonâ€metastatic HER2â€positive breast tumors: Multicentric study in Peru (NeoHer). <i>Molecular and Clinical Oncology</i> , 2022, 16, 70.	1.0	0
3	Impact of the Delayed Initiation of Adjuvant Chemotherapy in the Outcome of Triple Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2021, 21, 239-246.e4.	2.4	15
4	The impact of COVID-19 in the healthcare workforce in Peru. <i>Journal of Public Health Policy</i> , 2021, 42, 182-184.	2.0	19
5	Telemedicine and the current opportunities for the management of oncological patients in Peru in the context of COVID-19 pandemic. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103129.	4.4	21
6	Epidemiologic Patterns of COVID-19 Incidence in the Province of Lima. <i>Annals of Epidemiology</i> , 2021, 54, 27-28.	1.9	3
7	Biological bases of cancer immunotherapy. <i>Expert Reviews in Molecular Medicine</i> , 2021, 23, e3.	3.9	14
8	PUM1 and RNase P genes as potential cellâ€free DNA markers in breast cancer. <i>Journal of Clinical Laboratory Analysis</i> , 2021, 35, e23720.	2.1	4
9	Near-Complete Genome Sequences of 12 Peruvian Strains of Infectious Hypodermal and Hematopoietic Necrosis Virus Infecting the Shrimp <i>Penaeus vannamei</i> . <i>Microbiology Resource Announcements</i> , 2021, 10, .	0.6	0
10	Characteristics of COVID-19 in cancer patients: a cross-sectional study in Peru. <i>Ecancermedicalscience</i> , 2021, 15, 1246.	1.1	0
11	Profile of entrectinib in the treatment of ROS1-positive non-small cell lung cancer: Evidence to date. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, 14, 192-198.	0.9	4
12	Thrombosis in abdominal vessels associated with COVID-19 Infection: A report of three cases. <i>Radiology Case Reports</i> , 2021, 16, 3044-3050.	0.6	4
13	Influence of Sex in the Molecular Characteristics and Outcomes of Malignant Tumors. <i>Frontiers in Oncology</i> , 2021, 11, 752918.	2.8	6
14	Breast-conserving surgery vs. total mastectomy in patients with triple negative breast cancer in early stages: A propensity score analysis. <i>Breast Disease</i> , 2020, 39, 29-35.	0.8	8
15	Lung Cancer in the Young. <i>Lung</i> , 2020, 198, 195-200.	3.3	32
16	Breast cancer mortality trends in Peruvian women. <i>BMC Cancer</i> , 2020, 20, 1173.	2.6	7
17	Lymph node ratio as best prognostic factor in tripleâ€negative breast cancer patients with residual disease after neoadjuvant chemotherapy. <i>Breast Journal</i> , 2020, 26, 1659-1666.	1.0	6
18	The hispanic landscape of triple negative breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 155, 103094.	4.4	11

#	ARTICLE	IF	CITATIONS
19	Triple-negative breast cancer in Peru: 2000 patients and 15 years of experience. PLoS ONE, 2020, 15, e0237811.	2.5	12
20	The hidden impact of the clandestine abortion in Peru. Journal of Public Health Policy, 2020, 41, 228-229.	2.0	0
21	Clinical consequences of resistance to ALK inhibitors in non-small cell lung cancer. Expert Review of Respiratory Medicine, 2020, 14, 385-390.	2.5	6
22	Neutrophil-to-lymphocyte ratio predicts early mortality in females with metastatic triple-negative breast cancer. PLoS ONE, 2020, 15, e0243447.	2.5	6
23	Patterns of Mutation Enrichment in Metastatic Triple-Negative Breast Cancer. Clinical Medicine Insights: Oncology, 2019, 13, 117955491986848.	1.3	15
24	Precision medicine for locally advanced breast cancer: frontiers and challenges in Latin America. Ecancermedicalscience, 2019, 13, 896.	1.1	8
25	First report of a KELnull phenotype in Peru and a lesson of invisible genetic disparity. Transfusion and Apheresis Science, 2019, 58, 453-456.	1.0	1
26	Current knowledge of Ipilimumab and its use in treating non-small cell lung cancer. Expert Opinion on Biological Therapy, 2019, 19, 509-515.	3.1	16
27	Barriers in Latin America for the management of locally advanced breast cancer. Ecancermedicalscience, 2019, 13, 897.	1.1	20
28	ALK rearrangements: Biology, detection and opportunities of therapy in non-small cell lung cancer. Critical Reviews in Oncology/Hematology, 2019, 136, 48-55.	4.4	33
29	Helicobacter pylori: History and facts in Peru. Critical Reviews in Oncology/Hematology, 2019, 134, 22-30.	4.4	5
30	From colorectal cancer pattern to the characterization of individuals at risk: Picture for genetic research in Latin America. International Journal of Cancer, 2019, 145, 318-326.	5.1	14
31	EGFR-RAD51 Fusion: A Targetable Partnership Originated from the Tumor Evolution?. Journal of Thoracic Oncology, 2018, 13, e33-e34.	1.1	17
32	Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy?. ESMO Open, 2018, 3, e000344.	4.5	105
33	Primary and metastatic brain cancer genomics and emerging biomarkers for immunomodulatory cancer treatment. Seminars in Cancer Biology, 2018, 52, 259-268.	9.6	11
34	Effect of CCL5 expression in the recruitment of immune cells in triple negative breast cancer. Scientific Reports, 2018, 8, 4899.	3.3	91
35	Old myths about old patients: the case of non-small cell lung cancer. Translational Lung Cancer Research, 2018, 7, S362-S363.	2.8	0
36	In Vivo Diagnosis of Metastasis in Cervical Lymph Nodes Using Backscatter Coefficients. , 2018, , .		1

#	ARTICLE	IF	CITATIONS
37	DNA Damage Inducible Transcript 4 Gene: The Switch of the Metabolism as Potential Target in Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 106.	2.8	76
38	H-scan analysis of thyroid lesions. <i>Journal of Medical Imaging</i> , 2018, 5, 1.	1.5	13
39	Breast elastography: Identification of benign and malignant cancer based on absolute elastic modulus measurement using vibro-elastography. , 2018, , .		2
40	In silico evaluation of DNA Damage Inducible Transcript 4 gene (DDIT4) as prognostic biomarker in several malignancies. <i>Scientific Reports</i> , 2017, 7, 1526.	3.3	60
41	In vivo attenuation estimation in human thyroid nodules using the regularized spectral log difference technique: Initial pilot study. , 2017, , .		0
42	Mutational analysis of BRCA1 and BRCA2 genes in Peruvian families with hereditary breast and ovarian cancer. <i>Molecular Genetics & Genomic Medicine</i> , 2017, 5, 481-494.	1.2	14
43	In vivo attenuation estimation in human thyroid nodules using the regularized spectral log difference technique: Initial pilot study. , 2017, , .		2
44	History of the development of radiotherapy in Latin America. <i>Ecancermedicalscience</i> , 2017, 11, 784.	1.1	9
45	High Epidermal Growth Factor Receptor Mutation Rates in Peruvian Patients With Non-Small-Cell Lung Cancer: Is It a Matter of Asian Ancestry?. <i>Journal of Global Oncology</i> , 2017, 3, 429-430.	0.5	5
46	In silico validation of a prostate cancer recurrence prognostic signature based on pathways related to stem cells.. <i>Journal of Clinical Oncology</i> , 2017, 35, e23205-e23205.	1.6	1
47	Exosomes in semen: opportunities as a new tool in prostate cancer diagnosis. <i>Translational Cancer Research</i> , 2017, 6, S1331-S1338.	1.0	11
48	Abstract 2614: Decrease of benefit from immune checkpoint inhibitors in women with non-small cell lung cancer. , 2017, , .		0
49	Repeated observation of immune gene sets enrichment in women with non-small cell lung cancer. <i>Oncotarget</i> , 2016, 7, 20282-20292.	1.8	28
50	A prognostic signature based on three-genes expression in triple-negative breast tumours with residual disease. <i>Npj Genomic Medicine</i> , 2016, 1, 15015.	3.8	50
51	Automated segmentation and classification of cell nuclei in immunohistochemical breast cancer images with estrogen receptor marker. , 2016, 2016, 2399-2402.		7
52	Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence. <i>Science Translational Medicine</i> , 2016, 8, 334ra53.	12.4	105
53	Expression of DDIT4 Is Correlated with NOTCH1 and High Molecular Risk in Acute Myeloid Leukemias. <i>Blood</i> , 2016, 128, 5254-5254.	1.4	6
54	Abstract 738: Correlation between tumor infiltrating lymphocytes and CCL5 gene expression in chemotherapy-resistant triple negative breast cancer. , 2016, , .		0

#	ARTICLE	IF	CITATIONS
55	Abstract 115:In silicoevaluation of DNA-damage-inducible transcript 4 gene (DDIT4) in the outcome of several malignant tumors. , 2016, , .		0
56	PIK3CA mutated, hormonal receptors and HER2: individual targets but partnered in the escape to targeted therapy in breast cancer. Translational Cancer Research, 2016, 5, S789-S793.	1.0	0
57	Characterization of breast density in women from Lima, Peru. Proceedings of SPIE, 2015, , .	0.8	2
58	Experimental assessment of an automatic breast density classification algorithm based on principal component analysis applied to histogram data. Proceedings of SPIE, 2015, , .	0.8	1
59	Automatic breast density classification using a convolutional neural network architecture search procedure. Proceedings of SPIE, 2015, , .	0.8	25
60	PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers. Hematology/ Oncology and Stem Cell Therapy, 2014, 7, 142-148.	0.9	18
61	Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets. Cancer Discovery, 2014, 4, 232-245.	9.4	413
62	Lactate Dehydrogenase B: A Metabolic Marker of Response to Neoadjuvant Chemotherapy in Breast Cancer. Clinical Cancer Research, 2013, 19, 3703-3713.	7.0	119
63	Addition of amifostine to the CHOP regimen in elderly patients with aggressive non-Hodgkin lymphoma: a phase II trial showing reduction in toxicity without altering long-term survival. Hematology/ Oncology and Stem Cell Therapy, 2012, 5, 152-157.	0.9	1
64	Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Nature Medicine, 2012, 18, 1052-1059.	30.7	219
65	A gene expression signature of MEK pathway activation to predict survival in triple-negative breast cancer.. Journal of Clinical Oncology, 2012, 30, 1024-1024.	1.6	3
66	Topoisomerase II- β as a predictive factor of response to therapy with anthracyclines in locally advanced breast cancer. Breast, 2011, 20, 39-45.	2.2	9
67	Prognostic effect of hormone receptor status in early HER2 positive breast cancer patients. Hematology/ Oncology and Stem Cell Therapy, 2010, 3, 109-115.	0.9	14
68	Breast Cancer Classification According to Immunohistochemistry Markers: Subtypes and Association With Clinicopathologic Variables in a Peruvian Hospital Database. Clinical Breast Cancer, 2010, 10, 294-300.	2.4	119